Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 1
1984 1
1987 3
1989 3
1992 2
1993 2
1994 7
1995 5
1996 4
1997 4
1998 8
1999 3
2000 6
2001 7
2002 15
2003 9
2004 3
2005 4
2006 11
2007 13
2008 4
2009 7
2010 13
2011 12
2012 12
2013 8
2014 8
2015 17
2016 20
2017 22
2018 14
2019 16
2020 17
2021 15
2022 11
2023 11
2024 18
2025 22

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

319 results

Results by year

Filters applied: . Clear all
Page 1
Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC.
Olsen EA, Whittaker S, Willemze R, Pinter-Brown L, Foss F, Geskin L, Schwartz L, Horwitz S, Guitart J, Zic J, Kim YH, Wood GS, Duvic M, Ai W, Girardi M, Gru A, Guenova E, Hodak E, Hoppe R, Kempf W, Kim E, Lechowicz MJ, Ortiz-Romero P, Papadavid E, Quaglino P, Pittelkow M, Prince HM, Sanches JA, Sugaya M, Vermeer M, Zain J, Knobler R, Stadler R, Bagot M, Scarisbrick J. Olsen EA, et al. Among authors: foss f. Blood. 2022 Aug 4;140(5):419-437. doi: 10.1182/blood.2021012057. Blood. 2022. PMID: 34758074 Free PMC article.
T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.
Horwitz SM, Ansell S, Ai WZ, Barnes J, Barta SK, Brammer J, Clemens MW, Dogan A, Foss F, Ghione P, Goodman AM, Guitart J, Halwani A, Haverkos BM, Hoppe RT, Jacobsen E, Jagadeesh D, Jones A, Kallam A, Kim YH, Kumar K, Mehta-Shah N, Olsen EA, Rajguru SA, Rozati S, Said J, Shaver A, Shea L, Shinohara MM, Sokol L, Torres-Cabala C, Wilcox R, Wu P, Zain J, Dwyer M, Sundar H. Horwitz SM, et al. Among authors: foss f. J Natl Compr Canc Netw. 2022 Mar;20(3):285-308. doi: 10.6004/jnccn.2022.0015. J Natl Compr Canc Netw. 2022. PMID: 35276674
Hepatosplenic T-Cell Lymphomas.
Gowda L, Foss F. Gowda L, et al. Among authors: foss f. Cancer Treat Res. 2019;176:185-193. doi: 10.1007/978-3-319-99716-2_9. Cancer Treat Res. 2019. PMID: 30596219
Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study.
O'Connor OA, Horwitz S, Masszi T, Van Hoof A, Brown P, Doorduijn J, Hess G, Jurczak W, Knoblauch P, Chawla S, Bhat G, Choi MR, Walewski J, Savage K, Foss F, Allen LF, Shustov A. O'Connor OA, et al. Among authors: foss f. J Clin Oncol. 2015 Aug 10;33(23):2492-9. doi: 10.1200/JCO.2014.59.2782. Epub 2015 Jun 22. J Clin Oncol. 2015. PMID: 26101246 Free PMC article. Clinical Trial.
Efficacy and Safety of Denileukin Diftitox-Cxdl, an Improved Purity Formulation of Denileukin Diftitox, in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma.
Foss FM, Kim YH, Prince HM, Akilov OE, Querfeld C, Seminario-Vidal L, Fisher DC, Kuzel TM, Yannakou CK, Geskin LJ, Feldman T, Sokol L, Allen PB, Dang NH, Cabanillas F, Wong HK, Ooi CE, Xing D, Sauter N, Singh P, Czuczman M, Duvic M. Foss FM, et al. J Clin Oncol. 2025 Apr;43(10):1198-1209. doi: 10.1200/JCO-24-01549. Epub 2024 Dec 19. J Clin Oncol. 2025. PMID: 39700456 Free PMC article. Clinical Trial.
Global outcomes and prognosis for relapsed/refractory mature T-cell and NK-cell lymphomas: results from the PETAL consortium.
Han JX, Koh MJ, Boussi L, Sorial M, McCabe SM, Peng L, Singh S, Eche-Ugwu IJ, Gabler J, Fernandez Turizo MJ, MacVicar CT, Garg A, Disciullo A, Chopra K, Lenart A, Nwodo E, Barnes J, Koh MJ, Miranda E, Chiattone C, Stuver R, Horwitz SM, Merrill M, Jacobsen E, Manni M, Civallero M, Skrypets T, Lymboussaki A, Federico M, Kim Y, Kim JS, Cho JY, Eipe T, Shet T, Sridhar E, Shetty A, Saha S, Jain H, Sengar M, Van Der Weyden C, Prince HM, Hamouche R, Muradashvili T, Foss F, Gentilini M, Casadei B, Zinzani PL, Okatani T, Yoshida N, Yoon SE, Kim WS, Panchoo G, Mohamed Z, Verburgh E, Alturas JC, Al-Mansour M, Ford J, Cabrera ME, Ku A, Bhagat G, Ma H, Sawas A, Kariya KM, Iwasaki M, Bhanushali F, O'Connor OA, Marchi E, Shen C, Shah D, Jain S. Han JX, et al. Among authors: foss f. Blood Adv. 2025 Feb 11;9(3):583-602. doi: 10.1182/bloodadvances.2024014674. Blood Adv. 2025. PMID: 39481087 Free PMC article.
Peripheral T-cell lymphoma.
Foss FM, Zinzani PL, Vose JM, Gascoyne RD, Rosen ST, Tobinai K. Foss FM, et al. Blood. 2011 Jun 23;117(25):6756-67. doi: 10.1182/blood-2010-05-231548. Epub 2011 Apr 14. Blood. 2011. PMID: 21493798 Free article. Review.
Cutaneous T-cell lymphoma.
Lansigan F, Choi J, Foss FM. Lansigan F, et al. Among authors: foss fm. Hematol Oncol Clin North Am. 2008 Oct;22(5):979-96, x. doi: 10.1016/j.hoc.2008.07.014. Hematol Oncol Clin North Am. 2008. PMID: 18954747 Review.
Mycosis Fungoides and Sezary Syndrome.
Foss FM, Girardi M. Foss FM, et al. Hematol Oncol Clin North Am. 2017 Apr;31(2):297-315. doi: 10.1016/j.hoc.2016.11.008. Hematol Oncol Clin North Am. 2017. PMID: 28340880 Review.
Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM): a single-arm, open-label, phase 1, dose-escalation study.
Iyer SP, Sica RA, Ho PJ, Prica A, Zain J, Foss FM, Hu B, Beitinjaneh A, Weng WK, Kim YH, Khodadoust MS, Huen AO, Williams LM, Ma A, Huang E, Ganpule A, Nagar SD, Sripakdeevong P, Cullingford EL, Karnik S, Dequeant ML, Patel JN, He XS, Li Z, He QA, Mendonez JH, Keegan A, Horwitz SM. Iyer SP, et al. Among authors: foss fm. Lancet Oncol. 2025 Jan;26(1):110-122. doi: 10.1016/S1470-2045(24)00508-4. Epub 2024 Nov 29. Lancet Oncol. 2025. PMID: 39617017 Clinical Trial.
319 results